(S)-Crizotinib

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

(S)-Crizotinib  纯度: 99.61%

(S)-Crizotinib 是一种有效的选择性 MTH1 (mutT 同源物)抑制剂,IC50 为 330 nM。(S)-Crizotinib 通过抑制 MTH1 破坏核苷酸库的稳态,诱导 DNA 单链断裂的增加,激活人结肠癌细胞的 DNA 修复,并有效抑制动物模型中的肿瘤生长。

(S)-Crizotinib

(S)-Crizotinib Chemical Structure

CAS No. : 1374356-45-2

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ¥880 In-stock
5 mg ¥800 In-stock
10 mg ¥1200 In-stock
50 mg ¥2900 In-stock
100 mg ¥4500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

(S)-Crizotinib 相关产品

相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Cell Cycle/DNA Damage Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Drug Repurposing Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Anti-Lung Cancer Compound Library
  • Anti-Blood Cancer Compound Library
  • Targeted Diversity Library

生物活性

(S)-Crizotinib is a potent and selective MTH1 (mutT homologue) inhibitor with an IC50 of 330 nM. (S)-Crizotinib disrupts nucleotide pool homeostasis via MTH1 inhibition, induces an increase in DNA single strand breaks, activates DNA repair in human colon carcinoma cells, and effectively suppresses tumour growth in animal models[1].

IC50 & Target

IC50: 330 nM (MTH1)[1]

体外研究
(In Vitro)

(S)-crizotinib (0.625-80 μM; 24 hours) 降低了 NCI-H460,H1975 和 A549 细胞的活力,IC50 值分别为 14.29、16.54 和 11.25 μM[2]
(S)-crizotinib (10-30 μM; 24 hours) 诱导 NCI-H460,H1975 和 A549 细胞凋亡[2]
(S)-crizotinib (10-30 μM; 24 hour

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells
Concentration: 0.625, 1.25, 2.5, 5, 10, 20, 40, 60, 80 μM
Incubation Time: 24 hours
Result: Decreased the viability of NCI-H460, H1975 and A549 cells with IC50 values of 14.29, 16.54 and 11.25 μM, respectively.

Apoptosis Analysis[2]

Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells
Concentration: 10, 20 or 30 μM
Incubation Time: 24 hours
Result: Induced cells apoptosis.

Western Blot Analysis[2]

Cell Line: NSCLC cells, NCI-H460, H1975 and A549 cells
Concentration: 10, 20 or 30 μM
Incubation Time: 24 hours
Result: Decreased Bcl-2: Bax ratio.

体内研究
(In Vivo)

(S)-crizotinib (7.5 或 15 mg/kg;腹腔注射;每天一次,连续10天)可显着降低肿瘤体积和肿瘤重量[2]

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Five-week-old, athymic BALB/c nu/nu female mice (17-19 g) with NCI-H460 cells[2]
Dosage: 7.5 or 15 mg/kg
Administration: Intraperitoneal injections; once daily for 10 days
Result: Resulted in significant reductions in both tumor volume and tumor weight.

分子量

450.34

Formula

C21H22Cl2FN5O

CAS 号

1374356-45-2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 12.5 mg/mL (27.76 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2205 mL 11.1027 mL 22.2054 mL
5 mM 0.4441 mL 2.2205 mL 4.4411 mL
10 mM 0.2221 mL 1.1103 mL 2.2205 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.25 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (2.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.25 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (2.78 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 1.25 mg/mL (2.78 mM); Clear solution

    此方案可获得 ≥ 1.25 mg/mL (2.78 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 12.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Huber KV, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7.

    [2]. Dai X, et al. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J Exp Clin Cancer Res. 2017 Sep 7;36(1):120.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务